AG
CTIC

Algert Global’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Algert Global’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-339,349
Closed -$733K – 448
2018
Q3 		$733K Buy
339,349
+121,326
+56% +$300K 0.16% 209
2018
Q2 		$1.09M Buy
+218,023
New +$954K 0.23% 171

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Algert Global's CTIC Position: Q4 2018 in Review

Algert Global sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2018, closing a stake of 339,349 shares — an estimated $733K sold.

Algert Global first reported a position in CTIC in Q2 2018 and held it in 2 quarters. The position peaked at $1.09M in Q2 2018. 75 funds tracked by Wall St. Rank hold CTIC as of Q4 2018.

  • Algert Global reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2018 after selling out during the quarter.
  • Algert Global sold 339,349 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2018, an estimated $733K.
  • Algert Global first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2018 and held it in 2 quarters.
  • Algert Global's CTI BioPharma Corp. (DE) Common Stock position peaked at $1.09M in Q2 2018.
  • 75 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2018.

Based on Algert Global's 13F filing for Q4 2018, filed 1 Feb 2019.